Quotient (QTNT) Stock Price, News & Analysis

Company Overview

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.19 to $0.80
• 52-Week Range: N/A
• Volume: 5.81 million shs
• Average Volume: 437,886 shs
• Market Capitalization: $980,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Quotient Stock Analysis - MarketRank™

Quotient scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Quotient.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quotient are expected to grow in the coming year, from ($26.00) to ($12.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quotient is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quotient is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for QTNT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quotient does not currently pay a dividend.

Dividend Growth

Quotient does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.38

Short Interest

There is no current short interest data available for QTNT.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for QTNT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quotient insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.50% of the stock of Quotient is held by insiders. A high percentage of insider ownership can be a sign of company health.

QTNT Stock Analysis - Frequently Asked Questions

How were Quotient's earnings last quarter?

Quotient Limited (NASDAQ:QTNT) posted its earnings results on Thursday, August, 5th. The company reported ($9.60) EPS for the quarter, topping analysts' consensus estimates of ($10.40) by $0.80. The firm had revenue of $9.09 million for the quarter, compared to analysts' expectations of $9.10 million.

When did Quotient's stock split?

Shares of Quotient reverse split on the morning of Thursday, November 3rd 2022. The 1-40 reverse split was announced on Thursday, November 3rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quotient investors own include Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F), Wayfair (W), Zomedica (ZOM), Wells Fargo & Company (WFC) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/05/2021
• Today: 1/25/2025
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:QTNT
• CUSIP: N/A
• CIK: 1596946
• Web: www.quotientbd.com
• Phone: (122) 716-9800
• Fax: N/A
• Employees: 426
• Year Founded: 2008

Profitability

• EPS (Most Recent Fiscal Year): ($53.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-125,130,000.00
• Net Margins: -413.55%
• Pretax Margin: -411.03%
• Return on Equity: N/A
• Return on Assets: -88.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.79
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $38.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($56.17) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,580,000
• Free Float: 2,309,000
• Market Cap: $980,000.00
• Optionable: Optionable
• Beta: 2.32